journal article·2021-03-03Open access

Does Soluble Urokinase-Type Plasminogen Activator Receptor Level Predicts the Occurrence of Inflammatory Complications in Maxillofacial Surgery?

Marcin Kozakiewicz, Rafał Nikodem Wlazeł

Applied Sciences· Volume 11· Issue 5

Abstract

Soluble urokinase-type plasminogen activator receptor (suPAR) is a marker of immune activation and reflects a more distinct aspect of inflammation than C-reactive protein (CRP) does. The study concerns a clinically silent state of the immune system expressed by the level of suPAR, which could affect the occurrence of complications (non-life threatening) after scheduled procedures. The purpose was the evaluation of suPAR predictive value in minor maxillofacial surgery complication incidents. Eighty patients were tested for suPAR, CRP and a series of basic laboratory serum tests on 1 day before surgery. Complications of orthognathic and minor injuries treatments were reported. The suPAR level, expressed as a measure independent of the patient’s age (Index of Body Inflammation, IBI), was analyzed. The protein level was also assessed on postoperative day 3. Basic statistical analysis did not reveal any relevant dependence between suPAR (or IBI) and occurrence of minor complications. The application of factor analysis, artificial neural network and inclusion of chlorides, glycaemia, alanine transaminase (ALT), albumin and hemoglobin levels allowed to indicate the suPAR/IBI ranges associated with an increased risk of minor postoperative complications. Concluding, it seems that, in the current state of the knowledge, the monitoring of pre-operational suPAR level solely does not include sufficient predictive information for the occurrence of minor complications after maxillofacial surgery. The suPAR/IBI level should be combined with other patient characteristics to predict healing complications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cerebrovascular and Carotid Artery Diseases · Protease and Inhibitor Mechanisms · Blood Coagulation and Thrombosis Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Maxillofacial Surgery, Medical University of Lodz, 113 Żeromskiego str, 90-549 Lodz, Poland

Department of Laboratory Diagnostics and Clinical Biochemistry, Medical University of Lodz, 251 Pomorska str, 92-213 Lodz, Poland

Funding

Uniwersytet Medyczny w Lodzi

References (38)

Show source-provided references
1. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis10.1111/j.1478-3231.2011.02665.x ↗
2. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention10.1016/j.amjcard.2012.08.008 ↗
3. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy10.1002/jmv.21114 ↗
4. Association of adverse experiences and exposure to violence in childhood and adolescence with inflammatory burden in young people
5. Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood10.1111/jcpp.12928 ↗
6. Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: Protocol for a systematic review and meta-analysis10.1136/bmjopen-2019-036125 ↗
7. A guide to systematic review and meta-analysis of prognostic factor studies10.1136/bmj.k4597 ↗
8. Kozakiewicz, M., Trzcińska-Kubik, M., and Wlazeł, R.N. (2021). Index of body inflammation for maxillofacial surgery purpose—To make the soluble urokinase-type plasminogen activator receptor serum level independent on patient age. Appl. Sci., 11.10.3390/app11031345 ↗
9. Pleural fluid suPAR levels predict the need for invasive management in parapneumonic effusions10.1164/rccm.201911-2169OC ↗
10. Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP)—Progress in prediction of AP severity10.1016/j.pan.2016.11.005 ↗
11. Laboratory markers predicting severity of acute pancreatitis10.3109/10408363.2015.1051659 ↗
12. Sundaralingam, A., Bedawi, E.O., and Rahman, N.M. (2020). Diagnostics in pleural disease. Diagnostics, 10.10.3390/diagnostics10121046 ↗
13. Circulating CD40 autoantibody and suPAR synergy drives glomerular injury
14. Zhang, S., Breidenbach, J.D., Russell, B.H., George, J., and Haller, S.T. (2020). CD40/CD40L signaling as a promising therapeutic target for the treatment of renal disease. J. Clin. Med., 9.10.3390/jcm9113653 ↗
15. HIV-Associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases10.1038/s41467-020-16222-8 ↗
16. Soluble urokinase plasminogen activator receptor level in individuals of advanced age10.1038/s41598-020-72377-w ↗
17. Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
18. Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention
19. Comparative study on usefulness of gentamycin-containing collagen implants in the treatment of patients with osteitis and osteomyelitis of the craniofacial skeleton10.5604/12321966.1235182 ↗
20. Evaluation of prognostic value of selected biochemical markers in surgically treated patients with acute mediastinitis
21. Acute mediastinitis: Evaluation of clinical risk factors for death in surgically treated patients
22. Exposure to Ti4Al4V titanium alloy leads to redox abnormalities, oxidative stress, and oxidative damage in patients treated for mandible fractures10.1155/2018/3714725 ↗
23. Borys, J., Maciejczyk, M., Antonowicz, B., Kretowski, A., Sidun, J., Domel, E., Dąbrowski, J., Ładny, J.R., Morawska, K., and Zalewska, A. (2019). Glutathione metabolism, mitochondria activity, and nitrosative stress in patients treated for mandible fractures. J. Clin. Med., 8.10.3390/jcm8010127 ↗
24. Expression of metalloproteinase 2 (MMP-2) and metalloproteinase 9 (MMP-9) in THP-1 macrophages cultured with three-dimensional titanium mini-plate systems used for surgical treatment of condylar fractures
25. The influence of the place of residence, smoking and alcohol consumption on bone mineral content in the facial skeleton10.1016/j.jtemb.2018.10.012 ↗
26. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients10.1016/j.jcrc.2013.08.005 ↗
27. suPAR—A future risk marker in bacteremia10.1111/j.1365-2796.2011.02372.x ↗
28. suPAR: The molecular crystal ball10.1155/2009/504294 ↗
29. uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK10.1016/j.brainres.2008.06.115 ↗
30. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus10.1016/j.trsl.2013.07.003 ↗
31. Isola, G., Polizzi, A., Alibrandi, A., Williams, R.C., and Leonardi, R. (2020). Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor levels. J. Periodontol.10.1002/JPER.20-0242 ↗
32. The analysis of the soluble urokinase plasminogen activator receptor (suPAR) concentrations in the patients with dental restorations10.5604/01.3001.0013.7679 ↗
33. Immediate loading of dental implants placed in periodontally infected and non-infected sites: A 4-year follow-up clinical study10.1902/jop.2010.090666 ↗
34. Comparison of magnesium-enriched hydroxyapatite and porcine bone in human extraction socket healing: A histologic and histomorphometric evaluation
35. Corticocancellous porcine bone in the healing of human extraction sockets: Combining histomorphometry with osteoblast gene expression profiles in vivo
36. Dental implants placed in extraction sites grafted with different bone substitutes: Radiographic evaluation at 24 months10.1902/jop.2009.090156 ↗
37. Implant prosthetic rehabilitation in controlled HIV-positive patients: A prospective longitudinal study with 1-year follow-up10.1111/cid.12353 ↗
38. The ‘All-on-four’ protocol in HIV-positive patients: A prospective, longitudinal 7-year clinical study